RenovaCare appoints Schweinle to chief medical officer

RenovaCare Inc., a Roseland-based developer of patented technologies for stem cell regeneration, announced on Wednesday it has appointed its first chief medical officer: Dr. Jo Ellen Schweinle.

Schweinle previously served as senior medical officer at the U.S. Department of Health and Human Services; clinical director at Bayer Corp., GlaxoSmithKline, McNeil Pharmaceuticals, Chiron/Novartis, and VP Medical Affairs at Axcan Pharma.

“We are privileged to have Dr. Schweinle join our executive leadership team as an accomplished physician, scientist, and clinical investigator. She is a renowned medical voice and noted authority in the use of self-donated stem cells and burn therapies,” Alan L. Rubino, CEO and president, RenovaCare, said.

Schweinle began her career teaching and researching infectious diseases at the University of Texas, National Institutes of Health and at Yale University School of Medicine.

“I am honored to be joining RenovaCare, an innovator at the forefront of cell isolation and regenerative spray technologies that has set a new standard for next-generation cell spray therapies,” Schweinle said. “RenovaCare innovations for the treatment of burns and wounds, and for tissue and organ regeneration, have the potential to help improve the quality of life for millions around the world. I look forward to my new role at RenovaCare and opening new windows of opportunity for advancing patient care.”